Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination

Arthritis and Rheumatology

Volumn 68, Issue 9, 2016, Pages 2328-2337

  Yun, Huifeng ^a   Yang, Shuo ^a   Chen, Lang ^a   Xie, Fenglong ^a   Winthrop, Kevin ^b   Baddley, John W ^a   Saag, Kenneth G ^a   Singh, Jasvinder ^a   Curtis, Jeffrey R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GOUT; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION; VERY ELDERLY; YOUNG ADULT;

EID: 84983517785     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39670     Document Type: Article

References (38)

1. Cohen JI. Clinical practice: herpes zoster. N Engl J Med 2013;369:255–63.
2. Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:37.
3. Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, et al. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum Vaccin 2011;7:1130–6.
4. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9–20.
5. Weller TH. Varicella and herpes zoster: changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med 1983;309:1434–40.
6. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–84.
7. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54:922–8.
8. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003;36:877–82.
9. Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1–30.
10. Zostavax [package insert]. Whitehouse Station (NJ): Merck; 2011.
11. Wilson DD. Herpes zoster: a rash demanding careful evaluation. Nurse Pract 2014;39:30–6.
12. Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus 2013;22:238–44.
13. Guthridge JM, Cogman A, Merrill JT, Macwana S, Bean KM, Powe T, et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol 2013;40:1875–80.
14. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1–26.
15. Navathe A. The ASPE/CMS Multi-payer Claims Database (MPCD) for comparative effectiveness research initiative. URL: http://www.brookings.edu/~/media/events/2010/11/18-basic/amol-navathe-slides.pdf.
16. MacLean CH, Park GS, Traina SB, Liu HH, Hahn BH, Paulus HE, et al. Positive predictive value (PPV) of an administrative data-based algorithm for the identification of patients with rheumatoid arthritis (RA). Arthritis Rheum 2001;44 Suppl:S106.
17. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
18. Singh JA, Holmgren AR, Noorbaloochi S. Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum 2004;51:952–7.
19. Asgari MM, Wu JJ, Gelfand JM, Salman C, Curtis JR, Harrold LR, et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiol Drug Saf 2013;22:842–9.
20. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605–9.
21. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005;133:245–53.
22. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331–9.
23. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register. Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896–904.
24. Yun H, Kilgore ML, Curtis JR, Delzell E, Gary LC, Saag KG, et al. Identifying types of nursing facility stays using Medicare claims data: an algorithm and validation. Health Serv Outcomes Res Methodol 2010;10:100–10.
25. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308:43–9.
26. Russell ML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 2007;135:908–13.
27. Rimland D, Moanna A. Increasing incidence of herpes zoster among veterans. Clin Infect Dis 2010;50:1000–5.
28. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20:748–53.
29. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006;45:1370–5.
30. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431–8.
31. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309:887–95.
32. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625–39.
33. Public Health Agency of Canada. Canadian immunization guide. URL: http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php.
34. Papadopoulou D, Sipsas NV. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol Int 2014;34:151–63.
35. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414–22.
36. National Library of Medicine: National Institutes of Health. ClinicalTrials.gov results database: safety and effectiveness study of the live zoster vaccine in anti-TNF users (VERVE). URL: https://clinicaltrials.gov/ct2/show/NCT01967316.
37. Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005;40:169–74.
38. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti–TNF-α agents. JAMA 2009;301:737–44.